scholarly journals Clinical case of long-term pemetrexed-based chemotherapy treatment for pulmonary adenocarcinoma (ALA +)

2018 ◽  
pp. 68-72
Author(s):  
A. M. Lozhkina ◽  
M. A. Sviridenko ◽  
A. O. Cheremnykh ◽  
E. A. Filippova ◽  
M. A. Urtenova ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Clinical Case ◽  
Term Treatment ◽  
Small Cell ◽  
Chemotherapy Treatment ◽  
Small Cell Lung ◽  
First Line ◽  
Long Term Treatment ◽  
Alk Positive

The article describes a clinical case of ALK-positive non-small cell lung cancer and its long-term treatment with a chemotherapy drug pemetrexed as first-line regimen followed by pemetrexed maintenance therapy.

scholarly journals Successful long-term treatment of non–small cell lung cancer positive for RET rearrangement with pemetrexed

2019 ◽  
Vol Volume 12 ◽  
pp. 5355-5358
Author(s):  
Masayuki Takeda ◽  
Kazuko Sakai ◽  
Kazuto Nishio ◽  
Kazuhiko Nakagawa
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Term Treatment ◽  
Small Cell ◽  
Small Cell Lung ◽  
Long Term Treatment

Efficacy of platinum rechallenge chemotherapy in sensitive relapsed small cell lung cancer after a long-term treatment-free interval.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e18554-e18554
Author(s):  
Yasushi Murakami ◽  
Hideo Saka ◽  
Masahide Oki ◽  
Chiyoe Kitagawa ◽  
Yoshihito Kogure
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Term Treatment ◽  
Small Cell ◽  
Small Cell Lung ◽  
Free Interval ◽  
Long Term Treatment

scholarly journals Pneumonectomy with carinal resection in patients with non-small cell lung cancer: short and long-term results

2018 ◽  
Vol 20 (4) ◽  
pp. 36-40
Author(s):  
I A Dadyev ◽  
M M Davydov ◽  
A G Abdullaev ◽  
I O Kulik ◽  
Z A Ambalova ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Treatment Outcomes ◽  
Term Treatment ◽  
Small Cell ◽  
Small Cell Lung ◽  
Resection Group ◽  
Carinal Resection ◽  
Long Term Treatment ◽  
Short And Long Term

Objective. With to compare short- and long-term treatment outcomes of different carinal resection techniques in patients with non-small cell lung cancer (NSCLC) and carina involvement. Materials and methods. We performed retrospective nonrandomized clinical trial with following groups of patients: patients underwent pneumonectomy with sleeve carinal resection (47 patients); patients underwent pneumonectomy with marginal and wedge carinal resection (18 patients). Statistical analysis was made using Statistic 6.0 program. Case-control analysis of the both groups was performed to evaluate short- and long-term treatment outcomes of different carinal resection techniques in patients with NSCLC and carina involvement. Results. Frequency of non-surgical and surgical complications was 27.7% and 18.5% correspondingly. Postoperative mortality was 8.5% in sleeve carinal resection group and 11.1% in marginal and wedge carinal resection group. Five-year survival rates were 32.6% in sleeve carinal resection group and 11.1% in marginal wedge carinal resection group.

scholarly journals Ceritinib in the treatment of ALK-positive patients with nonsmall-cell lung cancer

2019 ◽  
pp. 37-41
Author(s):  
K. K. Laktionov ◽  
E. V. Reutova
Keyword(s):  
Lung Cancer ◽  
Cell Lung Cancer ◽  
Kinase Inhibitor ◽  
Nonsmall Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
First Line ◽  
Results Of Treatment ◽  
The Russian Federation ◽  
Alk Positive

Ceritinib is the second ALK tyrosine kinase inhibitor after crizotinib, registered in the Russian Federation for the treatment of ALKpositive patients with non-small cell lung cancer (NSCLC). Later alectinib was registered. Thus, we have the opportunity, firstly, to continue targeted therapy with second-generation drugs after progression on crizotinib, and secondly, the appointment of more active drugs in the first line provides the best results of treatment.

Sign in / Sign up

Export Citation Format

Share Document